文献速递类风湿关节炎

低剂量口服糖皮质激素与类风湿关节炎患者骨质疏松性骨折风险:基于CPRD的队列研究

Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

结果显示当前低剂量用药(≤7.5 mg泼尼松等效剂量/天)与整体骨质疏松性骨折风险无关(aHR 1.14,95%CI 0.98–1.33),但与临床椎体骨折风险升高相关(aHR 1.59,95%CI 1.11–2.29)。

要点

  • 当前低剂量口服糖皮质激素与RA患者整体骨质疏松性骨折风险无显著关联。
  • 当前低剂量口服糖皮质激素与临床椎体骨折风险升高显著相关。
  • 短期或长期使用低剂量口服糖皮质激素,结果均保持不变。

核心结论

  • RA患者即使接受低剂量口服糖皮质激素,临床椎体骨折风险仍增加,临床医生应予以关注。

主要发现

  • 共发生1640例骨质疏松性骨折。
  • 当前低剂量口服糖皮质激素(≤7.5 mg泼尼松等效剂量/天)与整体骨质疏松性骨折风险无关(aHR 1.14,95%CI 0.98–1.33)。
  • 当前低剂量口服糖皮质激素与临床椎体骨折风险升高相关(aHR 1.59,95%CI 1.11–2.29)。
  • 短期或长期使用低剂量口服糖皮质激素,结果均保持不变。

关键数值与推荐

  • 低剂量定义为≤7.5 mg泼尼松等效剂量/天。
  • 当前使用定义为最近处方在6个月内,近期使用为7–12个月,过去使用为>1年。

临床怎么用

  • 对接受低剂量口服糖皮质激素的RA患者,应警惕临床椎体骨折风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical trials have shown that low-dose glucocorticoid therapy in patients with RA reduces bone loss in hands or hip, but the effect on osteoporotic fractures is not yet clear. Therefore, we investigated the use of low-dose oral glucocorticoids and risk of osteoporotic fractures among patients with RA. METHODS: This was a cohort study including patients with RA aged 50+ years from the Clinical Practice Research Datalink between 1997 and 2017. Exposure to oral glucocorticoids was stratified by the most recent prescription in current (<6 months), recent (7-12 months) and past (>1 year) use, and average daily and cumulative doses. Risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis and ribs) was estimated by time-dependent Cox proportional-hazards models, adjusted for lifestyle parameters, comorbidities and comedications. Secondary analyses assessed osteoporotic fracture risk with a combination of average daily and cumulative doses of oral glucocorticoids. RESULTS: Among 15 123 patients with RA (mean age 68.8 years, 68% females), 1640 osteoporotic fractures occurred. Current low-dose oral glucocorticoid therapy (≤7.5 mg prednisolone equivalent dose/day) in patients with RA was not associated with overall risk of osteoporotic fractures (adjusted hazard ratio 1.14, 95% CI 0.98, 1.33) compared with past glucocorticoid use, but was associated with an increased risk of clinical vertebral fracture (adjusted hazard ratio 1.59, 95% CI 1.11, 2.29). Results remained unchanged regardless of a short-term or a long-term use of oral glucocorticoids. CONCLUSION: Clinicians should be aware that even in RA patients who receive low daily glucocorticoid doses, the risk of clinical vertebral fracture is increased.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Abtahi S, Driessen JHM, Burden AM, et al. Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. Rheumatology (Oxford). 2022. PMID: 34255815. doi:10.1093/rheumatology/keab548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。